VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions
Osheiza Abdulmalik(Children's Hospital of Philadelphia), Martin K. Safo(Virginia Commonwealth University), Jürgen Venitz(National Cancer Institute), Nancy Anabaraonye(Children's Hospital of Philadelphia), Qiukan Chen(Children's Hospital of Philadelphia), Mohini S. Ghatge(Children's Hospital of Philadelphia), Piyusha P. Pagare(Virginia Commonwealth University), Abdelsattar M. Omar(Al-Azhar University), Yan Zhang(Virginia Commonwealth University), Guoyan Xu(Children's Hospital of Philadelphia), Boshi Huang(Virginia Commonwealth University), Xiaomeng Xu(Virginia Commonwealth University), Faik N. Musayev(Virginia Commonwealth University)
Cited by 25
Related Papers
In vivo hematopoietic stem cell modification by mRNA delivery
|Science|2023|321
2‐Methoxyestradiol, a Promising Anticancer Agent
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2003|276
5‐hydroxymethyl‐2‐furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells<sup>†,‡</sup>
|British Journal of Haematology|2005|244
Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia
|Nature Communications|2016|212
G Protein–Coupled Receptor Deorphanizations
|The Annual Review of Pharmacology and Toxicology|2011|193